• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Seladelpar sodium salt Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5753892

Seladelpar sodium salt is an orally active and specific agonist of PPARdelta(EC50 of 2nM). More details

Please Inquire
Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Seladelpar sodium salt, Inhibitor
Full Product Name
Seladelpar sodium salt
Product Synonym Names
MBX-8025 sodium salt; RWJ-800025 sodium salt
Form/Format
Solid. Powder
Purity/Purification
98.00%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
466.45
Solubility
DMSO: 50mg/mL (107.19mM) Need ultrasonic
(<1mg/ml refers to the product slightly soluble or insoluble)
Formula
C21H22F3NaO5S
SMILES
O=C([O-])COC1=CC=C(SC[C@H](OCC)COC2=CC=C(C(F)(F)F)C=C2)C=C1C.[Na+]
Target & IC50
PPAR-delta: ic50 2nM (EC50)
In Vitro
body weight by ~18% (P<0.05) reduced by Seladelpar sodium salt(in atherogenic diet-fed Wt mice). In contrast, Seladelpar sodium salt produces minimal effect on body weight in atherogenic diet-fed foz/foz mice. Seladelpar sodium salt lowers serum alanine aminotransferase (ALT) levels in foz/foz mice (P<0.05) and similarly in Wt mice. Seladelpar sodium salt normalizes serum cholesterol and decreases triglycerides in both genotypes (P<0.05). Seladelpar sodium salt abolishes hepatocyte ballooning (P<0.05) and decreases the nonalcoholic fatty liver disease (NAFLD) activity score by ~50%. Alsosirius red-positive areas in foz/foz mice (P<0.05) significantly reduced by Seladelpar sodium salt [4].

Structure of Seladelpar sodium salt, inhibitor

Seladelpar sodium salt Inhibitor – Cat# MBS5753892

Product References and Citations for Seladelpar sodium salt, inhibitor

Sahebkar A, et al. New peroxisome proliferator-activated receptor agonists: potential treatment, for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2014 Mar;15(4):493-503.
Sahebkar A, et al. New peroxisome proliferator-activated receptor agonists: potential treatment, for atherogenic dyslipidemia and non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2014 Mar;15(4):493-503.
Bays HE, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011 Sep;96(9):2889-97.
Bays HE, et al. MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J Clin Endocrinol Metab. 2011 Sep;96(9):2889-97.
Choi YJ, et al. Effects of the PPAR-delta agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis. 2012 Feb;220(2):470-6.
Choi YJ, et al. Effects of the PPAR-delta agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis. 2012 Feb;220(2):470-6.
Haczeyni F, et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol Commun. 2017 Jul 31;1(7):663-674.
Haczeyni F, et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol Commun. 2017 Jul 31;1(7):663-674.

Other Notes

Small volumes of Seladelpar sodium salt, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Seladelpar sodium salt purchase

MBS5753892 is an inhibitor targeting Seladelpar sodium salt.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000